Search for a doctor

Maria Alice V. Willrich, Ph.D.

  1. Chemist
Request an Appointment

Publications

  1. Murray DL, Willrich MAV. Applications of Mass Spectrometry Proteomic Methods to Immunoglobulins in the Clinical Laboratory. Clin Chem. 2024 Dec 2; 70 (12):1422-1435
    View PubMed
  2. Meldrum KL, Swansiger AK, Koscho J, Miller L, Sausen J, Maus AD, Ladwig PM, Willrich MAV, Prell JS. Gabor Transform-Based Antibody Quantitation in Serum: An Interlaboratory Liquid Chromatography/High-Resolution Mass Spectrometry Investigation. Anal Chem. 2024 Oct 29; 96 (43):17413-17422 Epub 2024 Oct 16
    View PubMed
  3. Wang Q, Andress BD, Pazdernik VMK, Larson DR, Coker JD, Dasari S, Rajkumar V, Dispenzieri A, Murray DL, Willrich MAV. Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS Progression. Clin Chem. 2024 Oct 3; 70 (10):1268-1278
    View PubMed
  4. Karsten C, Grannas K, Bergman O, Moverare R, Roforth M, Willrich MAV, Snyder MR, Yang YK. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation. AAPS J. 2024 Jul 24; 26 (5):86 Epub 2024 July 24
    View PubMed
  5. Wurtz LI, Knyazhanskaya E, Sohaei D, Prassas I, Pittock S, Willrich MAV, Saadeh R, Gupta R, Atkinson HJ, Grill D, Stengelin M, Thebault S, Freedman MS, Diamandis EP, Scarisbrick IA. Identification of brain-enriched proteins in CSF as biomarkers of relapsing remitting multiple sclerosis. Clin Proteomics. 2024 Jun 16; 21 (1):42 Epub 2024 June 16
    View PubMed
  6. Farnsworth CW, Roemmich B, Spears GM, Murray DL, Dispenzieri A, Willrich MAV. Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains. Clin Chem Lab Med. 2024 Apr 25; 62 (5):929-938 Epub 2023 Dec 05
    View PubMed
  7. Ladwig PM, Rivard AL, Barbeln A, Maus A, Murray DL, Snyder MR, Willrich MAV. Infliximab Therapeutic monitoring by tryptic peptide LC-MS/MS method improvements lead to improved accuracy with decreased imprecision and turnaround time. J Mass Spectrom Adv Clin Lab. 2024 Apr; 32:24-30 Epub 2024 Feb 03
    View PubMed
  8. Jain D, Pido MTJ, Delgado JC, Willrich MAV, Lazar-Molnar E. Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab. J Appl Lab Med. 2023 Nov 2; 8 (6):1054-1064
    View PubMed
  9. Galior KD, Ladwig PM, Snyder MR, Algeciras-Schimnich A, Bornhorst JA, Block DR, Baumann NA, Willrich MAV. Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays. Clin Biochem. 2023 Nov; 121-122:110685 Epub 2023 Nov 14
    View PubMed
  10. Al-Bawardy B, Jenkins SM, Snyder MR, Frinack JL, Ladwig PM, Loftus EV Jr, Willrich MAV. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clin Biochem. 2023 Sep; 119:110618 Epub 2023 July 26
    View PubMed
  11. Moonen DH, Kohlhagen M, Dasari S, Willrich MA, Kourelis T, Dispenzieri A, Murray DL. Utilizing Mass Spectrometry to Detect and Isotype Monoclonal Proteins in Urine: Comparison to Electrophoretic Methods. Clin Chem. 2023 Jul 5; 69 (7):746-753
    View PubMed
  12. Rozenova K, Willrich M, Snyder M, Dasari S, Kourelis T, Rajkumar SV, Kumar S, Dispenzieri A, Murray DL. Kappa Free Light Chain Drift Prompts the Need for a New Upper Limit of Normal Free Light Chain Ratio to Avoid an Epidemic of Kappa Light Chain Monoclonal Gammopathy of Undermined Significance. J Appl Lab Med. 2023 Jul 5; 8 (4):742-750
    View PubMed
  13. Acosta-Medina AA, Moyer AM, Go RS, Willrich MAV, Fervenza FC, Leung N, Bourlon C, Winters JL, Spears GM, Bryant SC, Sridharan M. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv. 2023 Feb 14; 7 (3):340-350
    View PubMed
  14. Hegen H, Walde J, Berek K, Arrambide G, Gnanapavan S, Kaplan B, Khalil M, Saadeh R, Teunissen C, Tumani H, Villar LM, Willrich MAV, Zetterberg H, Deisenhammer F. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 2023 Feb; 29 (2):169-181 Epub 2022 Dec 01
    View PubMed
  15. Hegen H, Arrambide G, Gnanapavan S, Kaplan B, Khalil M, Saadeh R, Teunissen C, Tumani H, Villar LM, Willrich MAV, Zetterberg H, Deisenhammer F. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Mult Scler. 2023 Feb; 29 (2):182-195 Epub 2022 Dec 17
    View PubMed
  16. Marzinke MA, Clarke W, Dietzen DJ, Hoofnagle AN, McMillin GA, Willrich MAV. The VALIDity of Laboratory Developed Tests: Leave it to the experts? J Mass Spectrom Adv Clin Lab. 2023 Jan; 27:1-6 Epub 2022 Dec 09
    View PubMed
  17. Sridharan M, Go RS, Willrich MAV. Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy. Mayo Clin Proc Innov Qual Outcomes. 2022 Oct; 6 (5):458-464 Epub 2022 Sept 17
    View PubMed
  18. Saadeh RS, Ramos PA, Algeciras-Schimnich A, Flanagan EP, Pittock SJ, Willrich MA. An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and Beyond. Clin Chem. 2022 Sep 1; 68 (9):1134-1150
    View PubMed
  19. Saadeh RS, Bryant SC, McKeon A, Weinshenker B, Murray DL, Pittock SJ, Willrich MAV. CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clin Proc. 2022 Apr; 97 (4):738-751 Epub 2021 Dec 08
    View PubMed
  20. Dasari S, Kohlhagen MC, Dispenzieri A, Willrich MAV, Snyder MR, Kourelis TV, Lust JA, Mills JR, Kyle RA, Murray DL. Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. Mayo Clin Proc. 2022 Feb; 97 (2):294-307 Epub 2021 Dec 07
    View PubMed
  21. Willrich MAV. Commentary on Significance of Monoclonal Band in Cerebral Spinal Fluid. Clin Chem 2022 Feb 1; 68 (2):281
    View PubMed
  22. Miller ID, Kohlhagen MC, Ladwig PM, Dasari S, Kumar S, Dispenzieri A, Willrich MAV, Murray DL. Characterizing M-protein light chain glycosylation via mass spectrometry. Clin Biochem. 2022 Nov-Dec; 109-110:11-16. Epub 2022 Sep 13.
    View PubMed
  23. Fatica EM, Martinez M, Ladwig PM, Murray JD, Kohlhagen MC, Kyle RA, Kourelis T, Lust JA, Snyder MR, Dispenzieri A, Murray DL, Willrich MAV. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. Clin Biochem. 2021 Nov; 97:67-73 Epub 2021 Aug 09
    View PubMed
  24. Willrich MAV, Braun KMP, Moyer AM, Jeffrey DH, Frazer-Abel A. Complement testing in the clinical laboratory. Crit Rev Clin Lab Sci. 2021 Nov; 58 (7):447-478 Epub 2021 May 07
    View PubMed
  25. Mellors PW, Kohlhagen MC, Dasari S, Willrich MAV, Gertz MA, Kumar SK, Lacy MQ, Murray DL, Dispenzieri A. Belantamab mafodotin detection by MASS-FIX and immunofixation. Clin Chem Lab Med 2021 Oct 26; 59 (11):e430-e433 Epub 2021 June 11
    View PubMed
  26. Borren NZ, Paulides E, Frinack JL, Olson RN, Willrich MAV, van der Woude CJ, Ananthakrishnan AN. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. Dig Dis Sci. 2021 Oct; 66 (10):3548-3554 Epub 2020 Oct 10
    View PubMed
  27. Alrahmani L, Gonzalez Suarez ML, Cousin MA, Moyer AM, Willrich MAV, White WM, Wick MJ, Tostrud LJ, Narang K, Garovic VD. Quantitative Alterations in Complement Alternative Pathway and Related Genetic Analysis in Severe Phenotype Preeclampsia. Kidney360. 2021 Sep 30; 2 (9):1463-1472 Epub 2021 June 30
    View PubMed
  28. Knight V, Heimall JR, Chong H, Nandiwada SL, Chen K, Lawrence MG, Sadighi Akha AA, Kumanovics A, Jyonouchi S, Ngo SY, Vinh DC, Hagin D, Forbes Satter LR, Marsh RA, Chiang SCC, Willrich MAV, Frazer-Abel AA, Rider NL. A Toolkit and Framework for Optimal Laboratory Evaluation of Individuals with Suspected Primary Immunodeficiency. J Allergy Clin Immunol Pract. 2021 Sep; 9 (9):3293-3307.e6 Epub 2021 May 24
    View PubMed
  29. Fatica EM, Larkey NE, Gleue CA, Willrich MAV. A Case of Unexpected Hyperglycemia. Clin Chem. 2021 Aug 5; 67 (8):1056-1059
    View PubMed
  30. Ladwig PM, Willrich MAV. Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry. J Mass Spectrom Adv Clin Lab. 2021 Aug; 21:10-18 Epub 2021 Aug 12
    View PubMed
  31. Graden KC, Bennett SA, Delaney SR, Gill HE, Willrich MAV. A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests. Lab Med. 2021 Jul 1; 52 (4):315-328
    View PubMed
  32. Ramos GP, Al-Bawardy B, Braga Neto MB, Bledsoe AC, Quinn KP, Heron V, Willrich MAV, Johnson A, Chedid VG, Coelho-Prabhu N, Kisiel JB, Papadakis KA, Pardi D, Kane S, Tremaine WJ, Raffals L, Bruining DH, Faubion WA, Harmsen WS, Loftus EV Jr. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohns Colitis 360. 2021 Jul; 3 (3):otab019 Epub 2021 May 17
    View PubMed
  33. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021 Jun 7; 11 (6):110 Epub 2021 June 07
    View PubMed
  34. Kohlhagen MC, Mills JR, Willrich MAV, Dasari S, Dispenzieri A, Murray DL. Clearing drug interferences in myeloma treatment using mass spectrometry. Clin Biochem. 2021 Jun; 92:61-66 Epub 2021 Mar 07
    View PubMed
  35. Sethi A, Miao J, Willrich MAV, Frinack JL, Cattran DC, Fervenza FC, MENTOR study Investigators//MENTOR study investigators. Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy. Clin J Am Soc Nephrol 2021 Jun; 16 (6):939-941 Epub 2021 Apr 15
    View PubMed
  36. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021 Mar 4; 11 (3):50 Epub 2021 Mar 04
    View PubMed
  37. Willrich MAV, Ladwig PM, Martinez MA, Sridharan MR, Go RS, Murray DL, Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays. J Immunol Methods. 2021 Mar; 490:112944 Epub 2020 Dec 13
    View PubMed
  38. Sadighi Akha AA, Tschumper RC, Mills JR, Isham CR, Witty EE, Viswanatha DS, Dasari S, Snyder MR, Murray DL, Katzmann JA, Jelinek DF, Willrich MAV. A rare case of selective Igkappa chain deficiency: Biologic and clinical implications. J Allergy Clin Immunol 2020 Nov; 146 (5):1208-1210.e6 Epub 2020 Apr 08
    View PubMed
  39. Sidana S, Murray DL, Dasari S, Go RS, Muchtar E, Willrich MA, Snyder M, Kohlhagen M, Lust JA, Kourelis TV, Kumar SK, Dispenzieri A, Gertz MA. Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. Am J Hematol 2020 Sep; 95 (9):E222-E225 Epub 2020 June 12
    View PubMed
  40. Kohlhagen M, Dasari S, Willrich M, Hetrick M, Netzel B, Dispenzieri A, Murray DL. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med. 2020 Aug 3; 59 (1):155-163 Epub 2020 Aug 03
    View PubMed
  41. Cradic KW, Ladwig PM, Rivard AL, Katrangi W, Wintgens KF, Willrich MAV. Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation. Clin Chem Lab Med. 2020 Jun 25; 58 (6):864-872
    View PubMed
  42. Turner KA, Frinack JL, Ettore MW, Tate JR, Graziani MS, Jacobs JFM, Booth RA, McCudden CR, Keren DF, Delgado JC, Zemtsovskaja G, Fullinfaw RO, Caldini A, de Malmanche T, Katakouzinos K, Burke M, Palladini G, Altinier S, Zaninotto M, Righetti G, Melki MT, Bell S, Willrich MAV. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clin Chem Lab Med. 2020 Mar 26; 58 (4):533-546
    View PubMed
  43. Jacobs JFM, Turner KA, Graziani MS, Frinack JL, Ettore MW, Tate JR, Booth RA, McCudden CR, Keren DF, Delgado JC, Zemtsovskaja G, Fullinfaw RO, Caldini A, de Malmanche T, Katakouzinos K, Burke M, Palladini G, Altinier S, Zaninotto M, Righetti G, Melki MT, Bell S, Willrich MAV. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med. 2020 Mar 26; 58 (4):547-559
    View PubMed
  44. Park SH, Al-Bawardy B, Aniwan S, Kane SV, Coelho-Prabhu N, Papadakis KA, Kisiel JB, Bruining DH, Faubion WA, Raffals LE, Pardi DS, Tremaine WJ, Stephens MC, Tung J, Khanna S, Willrich, Loftus EV. Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease. Crohn's & Colitis 360. 2019; 1(3):otz047.
  45. Murray DL, Willrich MAV. Evolution of Myeloma Testing in Clinical Chemistry with Mass Spectrometry. J Appl Lab Med 2019 Nov; 4 (3):474-476
    View PubMed
  46. Turner KA, Eckelkamp LL, Kalass SJ, Martinez MA, Brewer HR, Hoyne JB, Snyder MR, Murray DL, Willrich MAV. Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay. Clin Chem 2019 Oct; 65 (10):1327-1329 Epub 2019 Aug 06
    View PubMed
  47. Sepiashvili L, Kohlhagen MC, Snyder MR, Willrich MAV, Mills JR, Dispenzieri A, Murray DL. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry. Clin Chem. 2019 Aug; 65 (8):1015-1022 Epub 2019 June 06
    View PubMed
  48. Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Feb 21; 25 (3):580-586
    View PubMed
  49. Willrich MAV. Analysis of Tryptic Peptides from Therapeutic Monoclonal Antibodies Using LC-MS/MS. Methods Mol Biol. 2019; 1872:85-99
    View PubMed
  50. Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc. 2018 Oct; 93 (10):1351-1362
    View PubMed
  51. Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods. 2018 Oct; 461:15-22 Epub 2018 July 19
    View PubMed
  52. Willrich MAV, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018 Sep; 460:63-71 Epub 2018 June 20
    View PubMed
  53. Mills JR, Kohlhagen MC, Willrich MAV, Kourelis T, Dispenzieri A, Murray DL. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood 2018 Aug 9; 132 (6):670-672 Epub 2018 June 11
    View PubMed
  54. Gurtner KM, Shosha E, Bryant SC, Andreguetto BD, Murray DL, Pittock SJ, Willrich MAV. CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clin Chem Lab Med. 2018 Jun 27; 56 (7):1071-1080
    View PubMed
  55. Alrahmani L, Willrich MAV. The Complement Alternative Pathway and Preeclampsia. Curr Hypertens Rep. 2018 May 1; 20 (5):40 Epub 2018 May 01
    View PubMed
  56. Willrich MAV, Lazar-Molnar E, Snyder MR, Delgado JC. Comparison of Clinical Laboratory Assays for Measuring Serum Infliximab and Antibodies to Infliximab. J Appl Lab Med. 2018 May 1; 2 (6):893-903
    View PubMed
  57. Willrich MAV, Murray DL, Kyle RA. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin Biochem. 2018 Jan; 51:38-47 Epub 2017 May 04
    View PubMed
  58. Willrich MAV. Therapeutic Monoclonal Antibodies in the Clinical Laboratory. J Appl Lab Med. 2017 Nov 1; 2 (3):454-457
    View PubMed
  59. Ladwig PM, Barnidge DR, Willrich MAV. Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory. Clin Vaccine Immunol. 2017 May; 24 (5) Epub 2017 May 05
    View PubMed
  60. Ladwig PM, Barnidge DR, Willrich MA. Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry. J Am Soc Mass Spectrom. 2017 May; 28(5):811-817. Epub 2016 Dec 21.
    View PubMed
  61. Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, Willrich MA, Barnidge DR, Dispenzieri A, Murray DL. Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clin Chem. 2016 Oct; 62 (10):1334-44 Epub 2016 Aug 18
    View PubMed
  62. Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thomé SD, Hook CC, Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc. 2016 Sep; 91(9):1189-211. Epub 2016 Aug 03.
    View PubMed
  63. Mills JR, Cornec D, Dasari S, Ladwig PM, Hummel AM, Cheu M, Murray DL, Willrich MA, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Specks U, Barnidge DR. Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Anal Chem. 2016 Jun 21; 88(12):6317-25. Epub 2016 Jun 03.
    View PubMed
  64. Moyer AM, Saenger AK, Willrich M, Donato LJ, Baumann NA, Block DR, Botz CM, Khan MA, Jaffe AS, Hanson CA, Karon BS. Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients. Clin Chem. 2016 Jun; 62 (6):824-30 Epub 2016 Mar 28
    View PubMed
  65. Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016 Jun 1; 54: (6)907-19.
    View PubMed
  66. Willrich MA, Ladwig PM, Andreguetto BD, Barnidge DR, Murray DL, Katzmann JA, Snyder MR. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. Clin Chem Lab Med. 2016 Jun 01; 54(6):1085-93.
    View PubMed
  67. Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol. 2016 Apr; 31 (4):683-7 Epub 2016 Jan 13
    View PubMed
  68. Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem. 2016; 77:1-75.
    View PubMed
  69. Barnidge DR, Kohlhagen MC, Zheng S, Willrich MA, Katzmann JA, Pittock SJ, Murray DL. Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry. J Neuroimmunol. 2015 Nov 15; 288:123-6.
    View PubMed
  70. Willrich MA, Murray DL, Barnidge DR, Ladwig PM, Snyder MR. Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS. Int Immunopharmacol. 2015 Sep; 28(1):513-20. Epub 2015 Jul 25.
    View PubMed
  71. Willrich MA, Wittwer CA, Baumann NA, Block DR. A dark-brown serum sample. Clin Chem. 2015 Jul; 61(7):999-1000.
    View PubMed
  72. Katzmann JA, Willrich MA, Kohlhagen MC, Kyle RA, Murray DL, Snyder MR, Rajkumar SV, Dispenzieri A. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. Clin Chem. 2015 Feb; 61(2):360-7. Epub 2014 Dec 01.
    View PubMed
  73. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 2015 Feb; 165 (2):270-82 Epub 2014 Sept 22
    View PubMed
  74. Barnidge DR, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich MA, Tschumper RC, Jelinek DF, Snyder MR, Dispenzieri A, Katzmann JA, Murray DL. Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry. J Proteome Res. 2014 Nov 7; 13(11):5198-205. Epub 2014 Aug 26.
    View PubMed
  75. Barnidge D, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich M, Tschumper R, et al. Quantifying Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions by Mass Spectrometry. Journal of Proteome Research [Original Research] 14. 2014.
  76. Willrich MA, Baudhuin LM. PCSK9 and the road less traveled: how an unconventional approach led to a major discovery. Clin Chem 2013 Aug; 59 (8):1283-4
    View PubMed
  77. Willrich MA, Rodrigues AC, Cerda A, Genvigir FD, Arazi SS, Dorea EL, Bernik MM, Bertolami MC, Faludi A, Largura A, Baudhuin LM, Bryant SC, Hirata MH, Hirata RD. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients. Clin Chim Acta. 2013 Jun 5; 421:157-63. Epub 2013 Mar 15.
    View PubMed
  78. Rodrigues AC, Sobrino B, Genvigir FD, Willrich MA, Arazi SS, Dorea EL, et al. Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response. Clin Chim Acta. 2013 Feb 18; 417:8-11.
  79. Silbiger VN, Hirata MH, Luchessi AD, Genvigir FD, Cerda A, Rodrigues AC, et al. Differentiation of African components of ancestry to stratify groups in a case-control study of a Brazilian urban population. Genet Test Mol Biomarkers. 2012 Jun; 16(6):524-30.
  80. Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, et al. Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c. 388A>G Variant Is Determinant of Increased Atorvastatin Response Int J Mol Sci. 2011; 12(9):5815-27.
  81. Cerda A, Genvigir FD, Willrich MA, Arazi SS, Bernik MM, Dorea EL, et al. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin. Lipids Health Dis. 2011; 10:206.
  82. Cerda A, Genvigir FD, Rodrigues AC, Willrich MA, Dorea EL, Bernik MM, et al. Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. J Atheroscler Thromb. 2011; 18(8):640-51.
  83. Genvigir FD, Rodrigues AC, Cerda A, Arazi SS, Willrich MA, Oliveira R, et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics. 2010 Sep; 11(9):1235-46.
  84. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009 Jun; 10(6):1017-24.
  85. Rebecchi IM, Rodrigues AC, Arazi SS, Genvigir FD, Willrich MA, Hirata MH, et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol 1. 2009 Jan 1; 77(1):66-75.
  86. Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta. 2008 Dec; 398(1-2):15-20.
  87. Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Dorea EL, Bernik M, et al. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. Clin Chim Acta. 2008 Jul 17; 393(2):119-24.
  88. Genvigir FD, Soares SA, Hirata MH, Willrich MA, Arazi SS, Rebecchi IM, et al. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clin Chim Acta. 2008 Mar; 389(1-2):79-8.
  89. Silva FR, Szpoganicz B, Pizzolatti MG, Willrich MA, de Sousa E. Acute effect of Bauhinia forficata on serum glucose levels in normal and alloxan-induced diabetic rats. J Ethnopharmacol. 2002 Nov; 83(1-2):33-7.
PST-20514415